Long-term Real World-effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets in Subjects With Allergic Rhinitis With or Without Asthma: Results From a Multinational, Retrospective Register Study
Latest Information Update: 24 Jul 2026
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary) ; Timothy grass pollen allergen extract (Grastek) (Primary)
- Indications Allergic rhinitis; Asthma
- Focus Therapeutic Use
- Acronyms RELY
- Sponsors ALK-Abello
Most Recent Events
- 20 Jul 2026 Status changed from active, no longer recruiting to completed.
- 31 Jul 2023 Planned number of patients changed from 40000 to 49844.
- 31 Jul 2023 Planned End Date changed from 30 Jun 2024 to 1 Jun 2024.